Table 3.
List of the clinical trials and observational studies related to inulin [190].
| Title | Status | Conditions | Interventions | Identifier | Phase |
|---|---|---|---|---|---|
| Atorvastatin calcium, oligofructose-enriched inulin, or sulindac in preventing cancer in patients at increased risk of developing colorectal neoplasia | Completed | Colon cancer; precancerous condition; rectal cancer | Drug: oligofructose-enriched inulin (Raftilose Synergy1: a commercially available powder containing 90 to 94 %, wt/wt inulin and oligofructose, glucose and fructose (4 to 6 %, wt/wt), and sucrose (2 to 4 %, wt/wt; 6 g twice daily); Drug: sulindac; Drug: placebo; Drug: atorvastatin calcium; Other: laboratory biomarker analysis | NCT00335504 | Phase 2 |
| Using probiotics to reactivate tumor suppressor genes in colon cancer | Completed | Colon cancer | Dietary supplement: ProBion Clinica (equivalent to a dose of 1.4 × 1010 Bifidobacterium lactis bl-04 (ATCC sd5219), 7 × 109 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin) | NCT03072641 | NA |
| Mixture of prebiotics on intestinal microbiota of patients receiving abdominal radiotherapy. | Completed | Prebiotics; microbiota; radiation therapy complication; endometrial neoplasms | Dietary supplement: 6 g of fiber containing inulin (50 %) and fructo-oligosaccharide (50 %); Dietary supplement: maltodextrin (a homo-oligomer containing 3 to 17 glucose residues per chain) | NCT01549782 | NA |
| Prevention of febrile neutropenia by synbiotics in pediatric cancer patients | Unknown status | Febrile neutropenia; neutropenia; infection in an immunocompromised host; cancer | Dietary supplement: Probio-Fix inum; Dietary supplement: Beneo Synergy 1 (oligofructose-enriched inulin); Other: placebo | NCT02544685 | Phase 2 |
| Synbiotics and gastrointestinal function related quality of life after colectomy for cancer | Completed | Colorectal neoplasms | Dietary supplement: Synbiotics (containing 2.5 g of each of the four fermentable fibers (prebiotics) such as b-glucan, inulin, pectin, and resistant starch; Dietary supplement: placebo | NCT01479907 | NA |
| Influence of sulindac and probiotics on the development of pouch adenomas in patients with familial adenomatous polyposis | Unknown status | Adenomatous polyposis coli | Drug: sulindac; Drug: VSL#3® (probiotic); Drug: probiotic-inulin (12 g/day) | NCT00319007 | Phase 2 |
| Inositol supplementation to treat PCOS (INSUPP-PCOS) | Recruiting | PCOS; anovulation; hyperandrogenism; insulin resistance; glucose intolerance; metabolic complication | Other: daily placebo (received maltodextrin and inulin); Drug: inositol | NCT03864068 | Phase 2 |
| Effect of dietary fiber intervention on patients with polycystic ovary syndrome | Not yet recruiting | PCOS | Dietary supplement: dietary intervention [dietary fiber containing inulin (4 g), resistant starch (4 g), and β-glucan (2 g)] | NCT05431816 | NA |
| The vascular and metabolic effects of sunitinib in patients with metastatic renal cell carcinoma | Completed | Hypertension; renal function; insulin sensitivity; renal cell carcinoma | Not provided | NCT01227213 | Observational study |
| Effect of dietary modification on microbiota in overweight and obese polycystic ovary syndrome patients | Unknown status | PCOS | Dietary supplement: dietary and lifestyle modification and probiotic SANPROBI super formula (containing seven live probiotic bacteria strains and two prebiotics, namely fructo-oligosaccharide, inulin); Other: placebo | NCT03325023 | Phase 4 |
Abbreviations: ATCC: American type cell culture; NA: not applicable; PCOS: polycystic ovary syndrome.